Kurma Partners

Kurma Partners stands as a prominent European venture capital organization dedicated exclusively to healthcare investments, currently managing assets totaling €470 million. The firm has strategically structured its operations around two specialized investment franchises to maximize expertise and market penetration in distinct healthcare segments. This focused approach allows Kurma to provide not just capital but also deep sector knowledge and strategic guidance to portfolio companies navigating the complex healthcare landscape across Europe.

The firm's first investment franchise, Kurma Biofund, concentrates on therapeutic innovations and breakthrough treatments addressing significant unmet medical needs. With its current active vehicle Kurma Biofund III (KBIII), the franchise targets promising biotech companies developing novel therapeutics across various stages of development. Kurma's therapeutic investments typically span areas such as rare diseases, oncology, neurology, and immunology, where scientific advances can translate into meaningful clinical outcomes and commercial opportunities.

Complementing its therapeutic focus, Kurma's second franchise centers on diagnostic technologies and digital health solutions through Kurma Diagnostics. The currently active Kurma Dx2 fund invests in companies developing innovative diagnostic tools, medical devices, and digital health platforms that can transform healthcare delivery, improve patient outcomes, and enhance clinical decision-making. This franchise recognizes the growing importance of precision medicine, AI-driven diagnostics, and digital transformation in modern healthcare systems.

As a specialized healthcare investor, Kurma Partners has built a reputation for its hands-on approach and extensive network within the European life sciences ecosystem. The firm typically engages with companies from early-stage development through critical growth phases, often participating in company formation and providing ongoing strategic support. Kurma's investment team combines scientific expertise with business acumen, enabling them to evaluate complex technologies while helping portfolio companies navigate regulatory pathways, clinical development challenges, and commercialization strategies in the highly regulated healthcare market.